These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 25579378)

  • 1. Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008).
    Lacouture ME; Morris JC; Lawrence DP; Tan AR; Olencki TE; Shapiro GI; Dezube BJ; Berzofsky JA; Hsu FJ; Guitart J
    Cancer Immunol Immunother; 2015 Apr; 64(4):437-46. PubMed ID: 25579378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.
    Morris JC; Tan AR; Olencki TE; Shapiro GI; Dezube BJ; Reiss M; Hsu FJ; Berzofsky JA; Lawrence DP
    PLoS One; 2014; 9(3):e90353. PubMed ID: 24618589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokeratin 10 and Ki-67 nuclear marker expression in keratoacanthoma and squamous cell carcinoma.
    Basta-Juzbasić A; Klenkar S; Jakić-Razumović J; Pasić A; Loncarić D
    Acta Dermatovenerol Croat; 2004; 12(4):251-6. PubMed ID: 15588557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming growth factor alpha expression helps to distinguish keratoacanthomas from squamous cell carcinomas.
    Ho T; Horn T; Finzi E
    Arch Dermatol; 1991 Aug; 127(8):1167-71. PubMed ID: 1863074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VCAM (CD-106) and ICAM (CD-54) adhesion molecules distinguish keratoacanthomas from cutaneous squamous cell carcinomas.
    Melendez ND; Smoller BR; Morgan M
    Mod Pathol; 2003 Jan; 16(1):8-13. PubMed ID: 12527707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pattern of TGFbeta receptor 1 expression differs between kras-mutated keratoacanthomas and squamous cell carcinomas of the skin.
    Berger F; Geddert H; Faller G; Werner M; Dimmler A
    Pathol Res Pract; 2014 Sep; 210(9):596-602. PubMed ID: 24954139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of cell-cycle proteins p53, p21 (WAF-1), PCNA and Ki-67 in benign, premalignant and malignant skin lesions with implicated HPV involvement.
    Lu S; Tiekso J; Hietanen S; Syrjänen K; Havu VK; Syrjänen S
    Acta Derm Venereol; 1999 Jul; 79(4):268-73. PubMed ID: 10429981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of desmosomal glycoproteins in keratoacanthoma and squamous cell carcinoma of the skin: an immunohistochemical aid to diagnosis.
    Krunic AL; Garrod DR; Smith NP; Orchard GS; Cvijetic OB
    Acta Derm Venereol; 1996 Sep; 76(5):394-8. PubMed ID: 8891017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor 2 mRNA-binding protein-3 as a marker for distinguishing between cutaneous squamous cell carcinoma and keratoacanthoma.
    Kanzaki A; Kudo M; Ansai S; Peng WX; Ishino K; Yamamoto T; Wada R; Fujii T; Teduka K; Kawahara K; Kawamoto Y; Kitamura T; Kawana S; Saeki H; Naito Z
    Int J Oncol; 2016 Mar; 48(3):1007-15. PubMed ID: 26782292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ki-67 may be useful in differentiating between keratoacanthoma and cutaneous squamous cell carcinoma.
    Scola N; Segert HM; Stücker M; Altmeyer P; Gambichler T; Kreuter A
    Clin Exp Dermatol; 2014 Mar; 39(2):216-8. PubMed ID: 24524559
    [No Abstract]   [Full Text] [Related]  

  • 11. Case Report of Multiple Keratoacanthomas and Squamous Cell Carcinomas in a Patient Receiving Pembrolizumab.
    Chaudhari S; Leon A; Levin E; Neuhaus I; Liao W
    J Drugs Dermatol; 2017 May; 16(5):513-515. PubMed ID: 28628690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in sialyl-Tn antigen expression between keratoacanthomas and cutaneous squamous cell carcinomas.
    Jensen P; Clausen OP; Bryne M
    J Cutan Pathol; 1999 Apr; 26(4):183-9. PubMed ID: 10335895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 protein expression and cell proliferation in non-neoplastic and neoplastic proliferative skin diseases.
    Batinac T; Zamolo G; Jonjić N; Gruber F; Petrovecki M
    Tumori; 2004; 90(1):120-7. PubMed ID: 15143984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant p53 oncogene expression in keratoacanthoma and squamous cell carcinoma.
    Stephenson TJ; Royds J; Silcocks PB; Bleehen SS
    Br J Dermatol; 1992 Dec; 127(6):566-70. PubMed ID: 1476915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Keratoacanthomas on recent tattoos: Two cases].
    Kluger N; Douvin D; Dupuis-Fourdan F; Doumecq-Lacoste JM; Descamps V
    Ann Dermatol Venereol; 2017 Dec; 144(12):776-783. PubMed ID: 29126557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structures of a pan-specific antagonist antibody complexed to different isoforms of TGFβ reveal structural plasticity of antibody-antigen interactions.
    Moulin A; Mathieu M; Lawrence C; Bigelow R; Levine M; Hamel C; Marquette JP; Le Parc J; Loux C; Ferrari P; Capdevila C; Dumas J; Dumas B; Rak A; Bird J; Qiu H; Pan CQ; Edmunds T; Wei RR
    Protein Sci; 2014 Dec; 23(12):1698-707. PubMed ID: 25209176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of cell cycle and apoptosis regulatory proteins in keratoacanthoma and squamous cell carcinoma.
    Batinac T; Zamolo G; Coklo M; Hadzisejdic I; Stemberger C; Zauhar G
    Pathol Res Pract; 2006; 202(8):599-607. PubMed ID: 16781827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p63 expression in normal skin and usual cutaneous carcinomas.
    Reis-Filho JS; Torio B; Albergaria A; Schmitt FC
    J Cutan Pathol; 2002 Oct; 29(9):517-23. PubMed ID: 12358808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous Epithelial Lesions Induced by N-Methyl-N-nitrosourea in Male Sprague-Dawley Rats: A Possible Animal Model for Human Keratoacanthoma.
    Yuki M; Yoshizawa K; Emoto Y; Yuri T; Kinoshita Y; Tsubura A; Kurokawa I
    Anticancer Res; 2016 Jan; 36(1):111-20. PubMed ID: 26722034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiating keratoacanthoma from squamous cell carcinoma-In quest of the holy grail.
    Nagarajan P
    J Cutan Pathol; 2020 Apr; 47(4):418-420. PubMed ID: 31893469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.